Safety of tuberculosis preventive treatment among people receiving or about to initiate immunosuppressive medications: a systematic review and meta-analysis
Clicks: 8
ID: 329387
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
2.1
/100
8 views
7 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #524 of 578 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 578 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: People receiving immunosuppressive medications are at increased risk of tuberculosis. Tuberculosis preventive treatment (TPT) can reduce risk, however its safety among these populations is uncertain. We conducted a meta-analysis to evaluate adverse events (AE) associated with TPT among people receiving or about to initiate immunosuppressive medications. METHODS: We searched MEDLINE, Cochrane, Health Star, and EMBASE (1952-May 1, 2025), for studies reporting AE during TPT among people receiving or about to initiate immunosuppressives. We used random-effects generalized linear mixed models with Hartung-Knapp 95% confidence intervals to estimate our primary outcome: pooled proportion of AE-related discontinuation, stratified by TPT regimen. RESULTS: We included 27 studies (3184 participants). Populations included biologics/steroids recipients and solid organ/hematopoietic transplant candidates/recipients. For the primary outcome (25 studies, 2802 participants), TPT regimens included 6-12-month mono-isoniazid regimens (1511 participants), 4-months mono-rifamycin regimens (228 participants), 3-month isoniazid-rifamycin combination regimens (990 participants), and 6-9-month fluoroquinolone-based regimens (73 participants). Only mono-isoniazid regimens were provided while receiving immunosuppressives. Pooled AE-related discontinuation was 5.3% (95% CI: 3.1-8.9%; I2=65.4%) for mono-isoniazid regimens, 4.4% (95% CI: 0.1-75.4%; I2=86.3%) for mono-rifamycin regimens, 2.0% (1.0-4.1%; I2=0.0%) for isoniazid-rifamycin combination regimens, and 6.9% (95% CI: 0-92.3%; I2=65.4%) for fluoroquinolone-based regimens. Proportions were similar when stratified by biologics/steroids and transplant populations. CONCLUSION: Overall, AE-related TPT discontinuation was like the broader TPT literature. AE-related discontinuation of TPT was lowest with rifamycin-containing regimens, but these were only provided prior to initiating immunosuppressives. Data on the safety of non-isoniazid regimens among people receiving immunosuppressives are needed.
| Reference Key |
openalex_W7213920691
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Anabel Selemon, Maria Lima Fernandes, Kamila Romanowski, Luca Melnychuk, Dick Menzies, Victoria J Cook, Dina Fisher, Rachel K Lim, Sarah K Brode, James C Johnston, Mayara Lisboa Bastos, Jonathon R Campbell |
| Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| Year | 2026 |
| DOI |
10.1093/cid/ciag584
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.